Prosecution Insights
Last updated: August 06, 2026

Yeditepe Universitesi

5 pending office actions • 3 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days

Portfolio Summary

5
Total Pending OAs
5
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

2
Overdue
0
Due this week
1
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (2)Due ≤ 30 days (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

2
Hard (40%)
2
Medium (40%)
1
Easy (20%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 + other1 (20%)
§103 only2 (40%)
§112 only1 (20%)
Multi-statute (no §101)1 (20%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

3
Life Sciences
60% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
2
Business / Other
40% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

50 h
Manual time on pending OAs
10 h
Time saved (low, 20%)
18 h
Time saved (mid, 35%)
0.4 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
KWON, JOHN SEUNGJAI 1 45.1% +20.2%
PRONZATI, GINA 1 67.6% +42.9%
SHOMER, ISAAC 1 63.3% +30.3%
PEEBLES, KATHERINE 1 36.3% +49.0%
ANTHOPOLOS, PETER 1 57.2% +59.0%

Hard Cases (2)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18270844 USE OF PLANT-DERIVED EXOSOMES FOR INDUCING DIFFERENTIATION OF STEM CELL SOURCES INTO CARTILAGE AND BONE CELLS SHOMER, ISAAC 24d overdue
18268997 FORMULATION COMPRISING ERBIUM BORATE FOR USE IN PREVENTION AND TREATMENT OF WOUND SCARS PEEBLES, KATHERINE 14d

Interview Candidates (5)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.

App #TitleExaminerDue in
18270844 USE OF PLANT-DERIVED EXOSOMES FOR INDUCING DIFFERENTIATION OF STEM CELL SOURCES INTO CARTILAGE AND BONE CELLS SHOMER, ISAAC 24d overdue
17273994 USE OF PLANT EXOSOMES FOR SHOWING MODULATING EFFECTS ON IMMUNE SYSTEM CELLS ANTHOPOLOS, PETER 3d overdue
18268997 FORMULATION COMPRISING ERBIUM BORATE FOR USE IN PREVENTION AND TREATMENT OF WOUND SCARS PEEBLES, KATHERINE 14d
18864037 USE OF SODIUM PENTABORATE PENTAHYDRATE AS A CHEMOTHERAPEUTIC AGENT KWON, JOHN SEUNGJAI
18843330 METHOD AND CULTURE MEDIUM FORMULATION WHICH CAN BE USED TO OBTAIN MOTOR NEURONS FROM PLURIPOTENT STEM CELL-DERIVED NEUROMESODERMAL STEM CELLS PRONZATI, GINA

Top Art Units

Art UnitApps
1612 1
1617 1
1611 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18864037 USE OF SODIUM PENTABORATE PENTAHYDRATE AS A CHEMOTHERAPEUTIC AGENT KWON, JOHN SEUNGJAI §103 Non-Final OA Pending Nov 08, 2024
18843330 METHOD AND CULTURE MEDIUM FORMULATION WHICH CAN BE USED TO OBTAIN MOTOR NEURONS FROM PLURIPOTENT STEM CELL-DERIVED NEUROMESODERMAL STEM CELLS PRONZATI, GINA §112 Non-Final OA Pending Sep 03, 2024
18270844 USE OF PLANT-DERIVED EXOSOMES FOR INDUCING DIFFERENTIATION OF STEM CELL SOURCES INTO CARTILAGE AND BONE CELLS SHOMER, ISAAC 1612 §101§102§103§112Other Non-Final OA 24d overdue Pending Jul 04, 2023
18268997 FORMULATION COMPRISING ERBIUM BORATE FOR USE IN PREVENTION AND TREATMENT OF WOUND SCARS PEEBLES, KATHERINE 1617 §102§103§112 Non-Final OA 14d Pending Jun 22, 2023
17273994 USE OF PLANT EXOSOMES FOR SHOWING MODULATING EFFECTS ON IMMUNE SYSTEM CELLS ANTHOPOLOS, PETER 1611 §103 Non-Final OA 3d overdue Pending Mar 05, 2021

Managing Yeditepe Universitesi's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month